Senseonics Holdings Reaffirmed H1 2024 Revenue $10M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2023 | $0.50 | Underperform | Jefferies |
| 8/19/2021 | $6.00 | Buy | HC Wainwright & Co. |
GERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetesCommercialization, now in process, driven by Senseonics' global commercial partner, Ascensia Diabetes Care, a subsidiary of PHC Holdings CorporationMercy health system inserted the
GERMANTOWN, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Management will hold a conference call to review the Company's third quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by nav
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights & Accomplishments: Generated revenue of $4.9 million in the second quarter of 2024, representing growth of more than 18% compared to the prior year period FDA review of the 510(k) submission for the next-generation 365-day Eversense® system and operational readiness activities continue to advance for planned fourth quarter 2024 product launch Continued to advance the collaboration
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
PRE 14A - Senseonics Holdings, Inc. (0001616543) (Filer)
D - Senseonics Holdings, Inc. (0001616543) (Filer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
Jefferies initiated coverage of Senseonics with a rating of Underperform and set a new price target of $0.50
HC Wainwright & Co. initiated coverage of Senseonics Holdings with a rating of Buy and set a new price target of $6.00
SVB Leerink downgraded Senseonics Holdings from Outperform to Market Perform and set a new price target of $3.00
GERMANTOWN, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November: Stifel 2024 Healthcare ConferenceFormat: Corporate overview and one-on-one meetingsDate: Tuesday, November 19, 2024Time: 9:10 am ETWebcast: Click here Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services ForumFormat: One-on-one meetingsDate: Thursday, November 21, 2024 Interested parties may access a live and recorde
GERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetesCommercialization, now in process, driven by Senseonics' global commercial partner, Ascensia Diabetes Care, a subsidiary of PHC Holdings CorporationMercy health system inserted the
GERMANTOWN, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a definitive agreement for the purchase and sale of 45,714,286 shares of its common stock at an offering price of $0.35 per share of common stock in a registered direct offering. Additionally, in a concurrent private placement, the Company has agreed to issue unregistered warrants to purchase up to 45,714,286 shares of common stock (the "Warrants"). The Warrants will have an exercise price of $
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
Gainers Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. Calidi Biotherapeutics (AME